NASDAQ · Health care

Propanc Biopharma, Inc. (PPCB)

It posted a net loss of $18.9M. In fiscal 2026 capital spending exceeded operating cash flow by $5.7M. At June 30, 2026 it held $832K in cash. Its latest periodic report to the SEC is the annual report (10-K) filed on September 25, 2026.

Price

$0.63

+4.74% on the day · September 25, 2026

52-week range $0.56 to $52.50

Market cap

$2.2M

What Propanc Biopharma, Inc. does

Propanc Biopharma, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker PPCB.

Revenue and profit by year

Net income

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal year	Revenue	Operating income	Net income	Diluted EPS	Free cash flow
2026	n/a	-$18.2M	-$18.9M	-$17.62	-$5.7M
2025	n/a	-$57.3M	-$58.9M	-$371.22	n/a
2024	n/a	-$1.5M	-$1.8M	-$35,510.38	n/a
2023	n/a	-$1.8M	-$2.7M	-$3,195,934.22	n/a
2022	n/a	-$2M	-$2.7M	-$87,408,800.97	n/a
2021	n/a	-$1.8M	-$2M	-$1,420,415.21	n/a

Full financial statements: income, balance sheet and cash flow

Next report expected around November 13, 2026.

Estimated from its filing rhythm: 52 weeks after its report of November 14, 2025. Not a date the company has announced. See the report calendar

Latest SEC filings

What Propanc Biopharma, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

September 25, 2026
Annual report 10-K · period to June 30, 2026Diluted EPS -$17.62 versus -$371.22.
August 21, 2026
Form DEF 14C filing DEF 14C
August 5, 2026
Form PRE 14C filing PRE 14C
July 17, 2026
IPO registration S-1
July 14, 2026
Executive or director change 8-K
May 14, 2026
Quarterly report 10-Q · period to March 31, 2026Diluted EPS -$0.28 versus -$12.50.
April 10, 2026
IPO registration S-1
March 31, 2026
Form DEF 14C filing DEF 14C
March 20, 2026
Form PRE 14C filing PRE 14C
March 19, 2026
Preliminary proxy statement PRE 14A

Recent insider filings (Forms 3, 4 and 144): 10, the latest on August 23, 2023. Insider transactions on SEC

All filings on SEC EDGAR

Questions about PPCB

What does Propanc Biopharma, Inc. do?

Propanc Biopharma, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker PPCB.

Is Propanc Biopharma, Inc. profitable?

No. In fiscal 2026 it reported a net loss of $18.9M.

When did Propanc Biopharma, Inc. last report?

Its most recent periodic report is the annual report (10-K) filed on September 25, 2026. It covers the period to June 30, 2026.

Similar companies

Compare PPCB with

Compare PPCB with any company

Follow PPCB

Get an email when Propanc Biopharma, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow PPCB: get an email when it files

Where the numbers come from

Financial figures are the values Propanc Biopharma, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.